Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines.

Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, Homer J, O'Hara J, Robinson M, Shaw R, Sloan P.

J Laryngol Otol. 2016 May;130(S2):S90-S96.

2.

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.

Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):667-677. doi: 10.1016/j.ijrobp.2016.07.020.

PMID:
27727063
3.

Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients?

Choi SH, Terrell JE, Bradford CR, Ghanem T, Spector ME, Wolf GT, Lipkus IM, Duffy SA.

Nicotine Tob Res. 2016 Dec;18(12):2216-2224.

PMID:
27613928
4.

Tobacco assessment in completed lung cancer treatment trials.

Peters EN, Warren GW, Sloan JA, Marshall JR.

Cancer. 2016 Nov 15;122(21):3260-3262. doi: 10.1002/cncr.30223. No abstract available.

PMID:
27459400
5.

Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Lai SY, Song J, Hobbs BP, Gunn GB, Beadle BM, Rosenthal DI, Garden AS, Kies MS, Papadimitrakopoulou VA, Schwartz DL, Hutcheson KA.

Laryngoscope. 2017 Apr;127(4):842-848. doi: 10.1002/lary.26153. Epub 2016 Jul 21.

PMID:
27440393
6.

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.

Zhao R, Choi BY, Lee MH, Bode AM, Dong Z.

EBioMedicine. 2016 Jun;8:30-9. doi: 10.1016/j.ebiom.2016.04.017. Review.

7.

Smoking status and symptom burden in surgical head and neck cancer patients.

Sterba KR, Garrett-Mayer E, Carpenter MJ, Tooze JA, Hatcher JL, Sullivan C, Tetrick LA, Warren GW, Day TA, Alberg AJ, Weaver KE.

Laryngoscope. 2017 Jan;127(1):127-133. doi: 10.1002/lary.26159.

PMID:
27392821
8.

Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.

Descamps G, Karaca Y, Lechien JR, Kindt N, Decaestecker C, Remmelink M, Larsimont D, Andry G, Hassid S, Rodriguez A, Khalife M, Journe F, Saussez S.

J Cancer Res Clin Oncol. 2016 Oct;142(10):2185-96. doi: 10.1007/s00432-016-2203-7.

9.
10.

Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.

Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI.

Eur J Cancer. 2016 Sep;64:1-11. doi: 10.1016/j.ejca.2016.05.008.

11.

HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies.

Dok R, Nuyts S.

Cancers (Basel). 2016 Mar 29;8(4). pii: E41. doi: 10.3390/cancers8040041. Review.

12.

Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma.

Wemmert S, Lindner Y, Linxweiler J, Wagenpfeil S, Bohle R, Niewald M, Schick B.

Oncol Lett. 2016 Mar;11(3):1661-1670.

13.

Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.

van Kempen PM, Noorlag R, Swartz JE, Bovenschen N, Braunius WW, Vermeulen JF, Van Cann EM, Grolman W, Willems SM.

Cancer Immunol Immunother. 2016 May;65(5):575-85. doi: 10.1007/s00262-016-1819-4.

14.

Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories.

Dahlstrom KR, Garden AS, William WN Jr, Lim MY, Sturgis EM.

J Clin Oncol. 2016 Jun 1;34(16):1848-54. doi: 10.1200/JCO.2015.64.6448.

PMID:
26884553
15.

Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches.

Swiecicki PL, Malloy KM, Worden FP.

World J Clin Oncol. 2016 Feb 10;7(1):15-26. doi: 10.5306/wjco.v7.i1.15. Review.

16.

Incidence of tonsillar cancer in northern Sweden: Impact of human papilloma virus.

Loizou C, Laurell G, Lindquist D, Öfverman C, Stefansson K, Nylander K, Olofsson K.

Oncol Lett. 2015 Dec;10(6):3565-3572.

17.

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.

Samuels SE, Tao Y, Lyden T, Haxer M, Spector M, Malloy KM, Prince ME, Bradford CR, Worden FP, Schipper M, Eisbruch A.

Oral Oncol. 2016 Mar;54:68-74. doi: 10.1016/j.oraloncology.2015.12.001.

18.
19.

A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.

Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J.

Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020.

20.

The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies.

Wierzbicka M, Szyfter K, Milecki P, Składowski K, Ramlau R.

Contemp Oncol (Pozn). 2015;19(4):313-22. doi: 10.5114/wo.2015.54389.

Supplemental Content

Support Center